Leeds spin-out to ease US wounds

Leeds spin-out Tissue Regenix has signed a processing partnership with US tissue bank Community Tissue Service, marking a major step forward for the commercialisation strategy of the Yorkshire-based medtech firm.

Founded in 2006, Tissue Regenix is commercialising a biological scaffolding technology which enhances healing in chronic wound conditions. 87% of patients treated with the firm’s medtech product, dCELL, have seen a reduction in the size of their wounds, whereas 60% had their wounds healed completely.

Community Tissue Services currently distributes 230,000 grafts annually. In the US, there are around 6.5m patients with chronic wounds, with care costs exceeding $25bn.

Greg Bila, president of the firm’s US subsidiary Tissue Regenix Wound Care, said: “We are delighted to announce this partnership with Community Tissue Services. This agreement will allow Tissue Regenix to advance our development and commercialisation of dCELL Dermis. We are excited to begin providing our dCELL technology to physicians and clinicians who treat patients suffering from chronic and acute wounds.”

David Smith, chief executive of Community Tissue Services, added: “We are extremely excited to partner with Tissue Regenix. Tissue Regenix’s dCELL Dermis will offer the latest technology in wound care management to patients suffering from acute and chronic wounds.”